

花蓮慈濟醫院研究部

排尿障礙治療中心-臨床組

主持人：郭漢崇醫師 研究成員：湯冬鈴、曾惠玲、田靜慧、彭惠貞

研究簡介

本實驗室是以研究排尿功能障礙的病人，其研究對象為脊髓損傷、膀胱過動症、攝護腺肥大、間質性膀胱炎的病患為主。我們藉由各種治療，例如服用抗膽鹼藥物、膀胱黏膜下、肌肉內或膀胱三角區注射肉毒桿菌毒素A，來評估病患在治療前與治療後的臨床療效，以其改善病患的排尿狀況及生活品質。對於於治療效果不佳的病患，我們也積極尋求更新的技術及治療方法，來提昇對於治療的整體滿意度。

計畫與經費來源

1. 探索K他命膀胱炎病人之病理生理學及各種不同臨床膀胱功能障礙之相關性=>MOST105-2314-B-303-015-MY3
2. 以微脂體包裹肉毒桿菌素(Lipotoxin)膀胱內灌注以治療間質性膀胱炎—多中心、隨機雙盲、安慰劑控制之前瞻性研究=>TCRD-I104-02
3. 以高濃度血小板血清(Platelet-Rich Plasma, PRP) 膀胱內注射以治療間質性膀胱炎=>TCRD106-01-E-106
4. 利用臨床病人特徵、共同疾病、表皮組織病理生理學、血清及尿液生物標記的不同，以繪製間質性膀胱炎疾病多樣性=>TCMMP105-02-05

研究成果

1. [Kuo HC](#), Liu HT, Chuang YC, Lori Birder, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: A single-center study. Eur Urol 2014; 65:1117-24.
2. Chuang YC, Kaufmann JH, Chancellor D, Chancellor MB, [Kuo HC](#). Bladder instillation of Liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: A prospective, multicenter, double-blind randomized trial. J Urol 2014; 192:1743-9.
3. Jiang YH, Liu HT, [Kuo HC](#). Urothelial dysfunction and chronic inflammation in patients with spinal cord injuries at different levels and correlation with urodynamic findings. Neurourol Urodyn 2015; 34:757-62.
4. Kuo YC, [Kuo HC](#). O'Leary-Sant Symptom index predicts the treatment outcome for onabotulinumtoxinA injections for refractory interstitial cystitis/bladder pain syndrome. Toxins 2015; 7:2860-71.
5. Lee CL, [Kuo HC](#). Long-term efficacy and safety of repeated intravesical onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/ bladder pain syndrome. Toxins 2015; 7:4283-93.
6. Liao CH, Chen SF, [Kuo HC](#). Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. Neurourol Urodyn 2016; 35:717-23.
7. [Kuo HC](#), Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment – a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn 2016; 35:609-14.
8. Kuo YC, [Kuo HC](#). Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis – different mechanism of action of Botox on bladder dysfunction. Toxins 2016; 8:E75.